Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

UCB (UCB)

Delayed Quote. Delayed  - 06/24 05:35:16 pm
64.72 EUR   -0.86%
06/10 UCB : bimekizumab demonstrates positive results in early development..
06/08 UCB : commitment to addressing real world patient needs on display a..
05/31 UCB : BRIVIACT® now available in U.S. pharmacies for epilepsy patien..
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
06/20/2016 06/21/2016 06/22/2016 06/23/2016 06/24/2016 Date
64.63(c) 65.19(c) 65.33(c) 65.28(c) 64.72(c) Last
242 702 283 368 257 260 218 008 424 340 Volume
+1.62% +0.87% +0.21% -0.08% -0.86% Change
More quotes
Financials (€)
Sales 2016 4 042 M
EBIT 2016 731 M
Net income 2016 453 M
Debt 2016 963 M
Yield 2016 1,93%
Sales 2017 4 285 M
EBIT 2017 889 M
Net income 2017 552 M
Debt 2017 573 M
Yield 2017 2,01%
P/E ratio 2016 25,28
P/E ratio 2017 20,48
EV / Sales2016 3,35x
EV / Sales2017 3,07x
Capitalization 12 588 M
More Financials
Company
UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products.It offers medicinal products for central nervous system and immunology disorders under the Cimzia, Xyzal, Zyrtec, Tussionex, Lortab, Vimpat, Keppra, and Neupro.The company was founded by... 
Sector
Pharmaceuticals
Calendar
07/28Earnings Release
More about the company
Surperformance© ratings of UCB
Trading Rating : Investor Rating :
More Ratings
Latest news on UCB
06/10 UCB : bimekizumab demonstrates positive results in early development in patients..
06/08 UCB : commitment to addressing real world patient needs on display at the Annual..
05/31 UCB : BRIVIACT® now available in U.S. pharmacies for epilepsy patients living wi..
05/19 UCB : Patent Issued for Systems for Automatically Administering Medication (USPT..
05/02 UCB FIRST THREE MONTHS INTERIM REPOR :
04/29 UCB : ex-dividend day for annual dividend
04/28 UCB : Patent Issued for Method for Producing Protein (USPTO 9315565)
04/28 UCB : shareholder meeting today
04/25 UCB FIRST THREE MONTHS INTERIM REPOR :
04/21 UCB : Patent Issued for Protein Purification (USPTO 9309280)
More news
Sector news : Pharmaceuticals - NEC
03:16a DEADLINE ALERT : Brower Piven Reminds Shareholders of Approaching Deadline In Cl..
06/24 BRISTOL MYERS SQUIBB : Sickle Cell Partnership Creates Demonstration Project to ..
06/24 SUN PHARMACEUTICAL : Pharma trades firm after board approves buyback of shares
06/24DJFRESENIUS SE KGAA : Germany's Fresenius Nears Deal to Acquire Pfizer's Medical D..
06/24DJSources Say Fresenius May Acquire Pfizer Medical Devices Arm for About $1.5 B..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
05/28 LANNETT : Structural Benefits Of The Kremers Acquisition: 100+% Upside
03/21 Amgen's romosozumab successful in late-stage study in men with osteoporosis
02/26 UCB backs out of epratuzumab development deal with Immunomedics
02/25 FDA clears Intellipharmaceutics' generic Keppra XR
02/22 Amgen's bone-forming antibody successful in late-stage osteoporosis study
Advertisement
Chart UCB
Duration : Period :
UCB Technical Analysis Chart | UCB | BE0003739530 | 4-Traders
Full-screen chart
Technical analysis trends UCB
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions